Introduction: Low-dose weekly methotrexate (MTX) is the mainstay in the therapy of
INTRODUCTION
The goal of rheumatoid arthritis (RA) treatment is to prevent joint damage, decrease pain, prevent functional impairment, and maintain or improve quality of life [1] . Currently, the use of disease-modifying antirheumatic drugs (DMARDs) is recommended as soon as the diagnosis is made to decrease or prevent disease progression and severity. However, the optimal therapeutic effect mediated by DMARDs is usually obtained after 4 to 6 months [2] .
As methotrexate (MTX) is a highly effective DMARD with a favorable efficacy/safety profile [3] , the S1 guideline for sequential medical treatment of active RA recommends that MTX should be administered before other DMARDs [4] . The advantage of subcutaneous (SC) MTX treatment is the linear dose absorption, which potentially improves the efficacy of SC MTX compared to oral administration of the same dosage [5] . Evidence of better efficacy and less gastrointestinal (GI) toxicity with parenteral versus oral MTX supports the recommendation of the Canadian Rheumatology Association and the Finnish Current Care Guidelines (Käypä hoito) to start treatment with SC MTX in DMARD naïve RA patients [6, 7] . Nonetheless, oral MTX is still the preferred treatment route [4, 8] . 
MATERIALS AND METHODS

Study Design
UMAR was a non-interventional, noncomparative, multicenter cohort study with retrospective data collection.
Study Medication
The with non-parametric methods, it was used in this study.
Non-parametric methods are reasonably easy to apply and avoid certain assumptions about data behavior. However, they are less effective than parametric methods regarding extrapolation of times exceeding the time horizon considered in the study. Thus, this analysis considered the following parametric methods: exponential, Weibull, log-logistic, and log-normal models [10] .
Statistical analysis was performed using 
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. Additional informed consent was obtained from all patients for whom identifying information is included in this article. 
RESULTS
A total of 50 patients' medical records were reviewed from the seven research centers that participated in the UMAR study. The main sociodemographic and clinical characteristics of patients included in this analysis are presented in Table 1 . 
Oral MTX treatment
Recorded AE of oral MTX included diarrhea (one patient), gastric intolerance (two patients), malaise (two patients), mucositis (one patient), nausea (three patients), and vomiting (two patients). The main reason for discontinuation of oral MTX was lack of efficacy (69.57%), followed by the occurrence of AE (28.26%), and a combination of both (2.17). The characterization of oral MTX treatment is presented in Table 2 . Twenty-three participants remained on the same dose of SC MTX, while eight (29.6%) and seventeen (70.4%) patients had a downward and an upward dose adjustment, respectively.
Only two patients presented more than one dosage adjustment: for one, SC MTX dose was In order to assess UMAR's endpoint, the duration of SC MTX treatment of all participants was evaluated regardless of dose changes during this period. Forty-one out of 50 patients were considered censored observations The sum differs (9 = 100%) since one participant discontinued the treatment due to more than one reason SD standard deviation, UMAR Utilization of Metoject Ò in Rheumatoid Arthritis (37 patients were still treated with SC MTX at the time of data collection and 4 patients had stopped SC MTX due to pregnancy or drug shortage). SC MTX discontinuation was recorded for only nine patients and was mainly a consequence of AEs (66.7%). Lack of efficacy was the cause of stopping SC MTX treatment in only three patients (Table 2 ). Due to the low number of occurrences and the short follow-up period, median time until SC MTX discontinuation was not observed (Fig. 3a) . The data collected suggest that the probability of discontinuation after 1, 2, and 3 years of treatment is expected to be 6.1% (CI 95%: 0-9.5%), 8.5% (CI 95%: 0.1-16.1%), and 23.2%
(CI 95%: 5.3-37.7%), respectively. Globally, the probability of UMAR participants remaining in treatment with MTX (oral and SC) over 5 years was 82.7% based upon Kaplan-Meier estimation.
To obtain predictions for the median duration of SC MTX treatment, parametric methods for survival analysis were used. For this purpose, several parametric models were adjusted to the data (Table 3 ; Fig. 3b In a post-marketing surveillance study, the tolerability and usability of self-administered high-dose SC MTX was tested for 5 weeks in patients with RA or psoriatic arthritis [11] . The formulation was generally well tolerated. In UMAR, the mean duration of oral MTX treatment prior to the SC formulation was 55.8 months, which we were unable to compare with other published studies since they lack this information. However, during this period, the mean weekly oral MTX dose of 14.3 mg was in accordance with the published values of 12.4-19.0 mg [19] [20] [21] . The literature also reveals a tendency towards the utilization of higher doses, probably due to differing levels of RA severity [19, [22] [23] [24] [25] . The main reason for discontinuation of oral MTX was lack of efficacy. In our study, discontinuation of SC MTX was more frequently due to AE than to lack of efficacy. UMAR participants reported several AEs related to oral MTX, predominantly GI AEs, which are well-known complications of this treatment [26] . However, as these data were collected separately, it cannot be assumed that the previously reported AEs were the reason of oral MTX discontinuation due to AEs.
Due to the limited patient follow-up this study presented only a small number of discontinuation events. For this reason, extrapolation using parametric survival models was required. Longer follow-up periods are recommended for future studies. The UMAR enquiry was subject to the usual limitations of a retrospective study: selection bias, information bias, and other problematic variables. Also results should be interpreted in light of the small sample size. 
